image

Pipeline Overview

Innovative Drugs Designed to Improve Patients’ Lives

Nurix is advancing three internally discovered and wholly owned clinical-stage drug-candidates designed to treat patients with hematologic malignancies and solid tumors. Nurix’s pipeline comprises both Targeted Protein Degraders to eliminate disease causing proteins and E3 ligase inhibitors that target key control elements in immune regulation (Targeted Protein Elevation). Drug discovery alliances with Gilead Sciences and Sanofi further enhance our pipeline, each focusing on the discovery and development of Targeted Protein Degraders against a set of unique targets.

Drug ProgramTarget/DeliveryTherapeutic AreaDiscoveryIND enablingPhase 1aPhase 1b
Targeted Protein Degradation
NX-2127 Degrader BTK + IKZF (Oral) B-cell malignancies

 

NX-5948 Degrader BTK (Oral) B-cell malignancies

 

NX-0479 / GS-6791 Degrader IRAK4 (Oral) Rheumatoid arthritis and other inflammatory diseases

 

Drug ProgramTarget/DeliveryTherapeutic AreaDiscoveryIND enablingPhase 1aPhase 1b
Targeted Protein Elevation
NX-1607 Inhibitor CBL-B (Oral) Immuno-oncology

 

Drug ProgramTarget/DeliveryTherapeutic AreaDiscoveryIND enablingPhase 1aPhase 1b
Discovery Pipeline
Wholly Owned 5 targets Undisclosed

 

Gilead Sciences 4 Targets Undisclosed

 

Sanofi 5 Targets Undisclosed

 

Targeted Protein Degradation
NX-2127 DegraderBTK + IKZF (Oral) - B-cell malignancies

Preclinical

IND-Enabling

Phase 1a

Phase 1b

 

NX-5948 DegraderBTK (Oral) - B-cell malignancies

Preclinical

IND-Enabling

Phase 1a

Phase 1b

 

NX-0479 / GS-6791 DegraderIRAK4 (Oral) - Rheumatoid arthritis and other inflammatory diseases

Preclinical

IND-Enabling

Phase 1a

Phase 1b

 

Targeted Protein Elevation
NX-1607 InhibitorCBL-B (Oral) - Immuno-oncology

Preclinical

IND-Enabling

Phase 1a

Phase 1b

 

Discovery Pipeline
Wholly Owned 5 targets - Undisclosed

Preclinical

IND-Enabling

Phase 1a

Phase 1b

 

Gilead Sciences4 Targets - Undisclosed

Preclinical

IND-Enabling

Phase 1a

Phase 1b

 

Sanofi5 Targets - Undisclosed

Preclinical

IND-Enabling

Phase 1a

Phase 1b